VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Lutzker on OX40 Agonist in Patients With Refractory Solid Tumors

Stuart Lutzker, MD, PhD
Published: Monday, May 23, 2016

Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.

OX40 is designed to provide co-stimulatory signals for T cells which can hopefully expand the pool of T-effector cells to treat disease, both as a single agent or in combination with atezolizumab, Lutzker explains.

Results of the phase I dose-escalation study show that were no dose-limiting toxicities in the 70 patients who were enrolled in the study. The majority of adverse events were grade 1/2, Lutzker says. Because of these findings, a phase Ib combination study with OX40 and atezolizumab is ongoing.
 
Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.

OX40 is designed to provide co-stimulatory signals for T cells which can hopefully expand the pool of T-effector cells to treat disease, both as a single agent or in combination with atezolizumab, Lutzker explains.

Results of the phase I dose-escalation study show that were no dose-limiting toxicities in the 70 patients who were enrolled in the study. The majority of adverse events were grade 1/2, Lutzker says. Because of these findings, a phase Ib combination study with OX40 and atezolizumab is ongoing.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x